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Introduction 
During last decade's prevalence of asthma increased
gradually. An intriguing finding is that the link
between atopic sensitization and asthma symptoms
increased with economic development [1]. Asthma is a
chronic inflammatory disorder which involves many
inflammatory cells and mediators [2,3]. The current
treatment of asthma is based on anti-inflammatory
drugs, mainly corticosteroids that intended to reduce
inflammatory process. However, corticosteroids are
very efficient in inhibiting airway inflammation; they
exert very mild effect on structural changes in the air-
ways [4,5]. The complexity of the natural course of the
disease prompts investigators to look for more effec-
tive therapy. 
Evidence is accumulating about the role of the
kynurenine pathway in the immune system regulation.
Tryptophan (TRP), an essential amino acid, is metabo-
lized mainly though kynurenine pathway by two dif-
ferent rate-limiting enzymes: tryptophan 2,3- dioxyge-
nase (TDO), located primarily in the liver, and
indoleamine 2,3- dioxygenase (IDO) found in many
immune system cells (eg. dendritic cells, monocytes,
macrophages) and tissues [6,7]. Tryptophan catabo-
lism leads to kynurenine (KYN) generation which has
been reported to possess important immunoregulatory
properties in vitro [8]. 
To study the immunological system regulation in
asthma a simple and sensitive models of asthma are
required. Rat, in comparison with other animals,
demonstrates many features of airway allergy and
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Abstract: Asthma is a chronic inflammatory disease that involves the immune system activation. Evidence is accumulating
about the role of kynurenine pathway in the immune system regulation. The kynurenine pathway includes several metabo-
lites of tryptophan, among others kynurenine (KYN). To study the immunological system regulation in asthma a simple and
sensitive models of asthma are required. In the present study we induced rat model of asthma using ovalbumin (OVA) sen-
sitization followed by challenge with OVA. The development of asthma has been confirmed by plasma total IgE measure-
ment and the histological examination. The concentration of KYN has been determined in plasma, lungs and liver by high-
performance liquid chromatography (HPLC). In OVA sensitized rats the concentration of total IgE was statistically signifi-
cantly increased as compared to VEH sensitized control groups (437.6 ± 97.7 kU/l vs 159.2 ± 22.7 kU/l, respectively; p<
0.01). In asthmatic animals, the number of eosinophils, neutrophils and mast cells increased considerably, and epithelial
lesion and the increase in airway epithelium goblet cells and edema of bronchial mucosa were present. We did not observe
any significant changes in the concentration of KYN in plasma, lungs or liver between studied groups. In conclusion, the
concentration of KYN remains unchanged in asthmatic animals as compared to control groups. Further studies using rat
model of asthma are warranted to establish the role of kynurenine pathway regulation in asthma. 
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allergic asthma that are similar to human [9]. The aim
of the present study was to establish ovalbumin
(OVA)-sensitized rat model of asthma and to evaluate
the concentration of KYN in asthmatic animals.
Materials and methods
Animals. 24 male Wistar rats (160-180 g) were housed in a room
with a 12 h light/dark cycle, in group cages as appropriate, given
tap water and fed a standard rat chow. 
Induction of experimental asthma in rats. Experimental asthma
was induced by ovalbumin (OVA) sensitization followed by OVA
challenge (n=6).
OVA sensitization. Sensitization was performed by intraperitoneal
injection of 200 μg/ml of OVA (Grade V; Sigma Chemical Co, St.
Louis, MO) (1 ml of OVA- Al(OH)3 suspension) on days 1, 2, 3,
and 11 of the experiment [10]. OVA was diluted in 400 μg/ml in
saline and precipitated at 1:1 ratio with Al(OH)3 (13 mg/ml, Alu-
minum hydroxide gel, Sigma Chemical Co, St. Louis, MO). On the
first day a foot pad injection of heat-killed Bordetella pertussis
(1010 in 50 μl saline) (Sigma Chemical Co, St. Louis, MO) was
given as an adjuvant. Control groups received saline-Al(OH)3
(VEH) immunization and foot pad injection of Bordetella pertus-
sis.
OVA challenge. Asthma was induced by allergen challenge. Start-
ing from day 19 and continuing for 7 consecutive days, the aller-
gen challenge was done with 1% OVA in saline [10]. This was
accomplished by placing rats in a plexiglas chamber 50×30 cm
connected to a nebulizer (pneumatic nebulizer Voyage, Poland)
generating an aerosol mist. Control groups received saline (VEH)
in the same manner. 
Control groups constituted: saline sensitized rats challenged
with VEH (VEH/VEH) (n=6), saline sensitized rats challenged
with OVA (VEH/OVA) (n=6), and OVA-sensitized rats challenged
with saline (OVA/VEH) (n=6). 
Blood withdrawing and total IgE measurement. 24 hours after
the last challenge, rats were anaesthetized with pentobarbital (40
mg/kg; ip) and blood was collected from the heart. Briefly, citrate
anticoagulated blood samples were immediately centrifuged at
3000 rpm for 20 min at 4 C and supernatants were aliquoted and
were frozen at -80°C until assay. Plasma total IgE measurement
was performed using rat IgE Elisa quantification kit (Bethyl Labo-
ratories.Inc). 
Tissue sampling. After blood withdrawing the lungs and the liver
were removed, sliced (60-100 mg of weight) and rapidly frozen on
ice. Samples were homogenized (100 mg/0.5 ml) in ice-cold 20%
trichloroacetic acid. Homogenates were centrifuged at 14000 × g
for 30 min and sonificated.
The determination of plasma, lung and liver KYN. The concen-
tration of kynurenine was determined by high-performance liquid
chromatography (HPLC) according to Holmes [11]. The reversed-
phase HPLC system consisted of a Waters Spherisorb S3 ODS2
150×2.1 mm column (USA), HP 1050 series pump (Germany),
Rheodyne injection valve fitted with a sample loop (5 μl). The col-
umn effluent was monitored using a UV detector HP 1050 (Ger-
many) - 365 nm. The output of the detector was connected to a sin-
gle instrument LC-2D ChemStation (Germany). The mobile phase
consisted of 0.1 M acetic acid, 0.1 M ammonium acetate (pH 4.65)
containing 1.8% of acetonitrile and was pumped at a flow-rate of
0.25 ml/min. Chromatography was carried out at 25°C. 
Method of experimental material collection and fixation. After
blood collection, the animals were sacrificed by cutting the heart.
Following a thoracotomy, the lungs were collected in whole.
Immediately after the preparation of the collected organ, Bouin's
fluid was administered by syringe into the trachea to smooth the
pulmonary pleura in the right lung. Following the ligation of tra-
chea, the lung was fixed in Bouin's fluid for 24 h in temperature of
+4°C. Then, following lobotomy from the circumference to the
hilus, the anterior part of the superior pulmonary lobe, directly
above the tracheal bifurcation, were routinely placed in paraffin
blocks and then sectioned by a Leica 2025 rotating microtome.
Applied routine histological staining methods. The obtained 
4-μm sections were stained with haematoxylin and eosin (H+E) for
general histological evaluation and by May-Grunwald solution at
35°C for 20 minutes, than stained in diluted Giemza solution in
35°C for 40 minutes. To study goblet cells in the bronchial epithe-
lium PAS staining method was used. 
Histological evaluation was performed by experienced histolo-
gist in a blinded fashion. The obtained results of immunohisto-
chemical staining were submitted for evaluation in an Olympus
Bx50 microscope. Mast cells and inflow elements (eosinophils,
neutrophils) were searched for along with their topography. 
Ethical issues. Procedures involving the animals and their care
were conducted in accordance with the institutional guidelines that
are in compliance with national and international laws and Guide-
lines for the Use of Animals in Biomedical Research (Thromb
Haemost 1987; 58: 1078-84). The study was approved by the local
Ethics Committee (21/2006).
Statistical analysis. The values are expressed as the mean ± SD,
n- represents the number of experiments. Muliple groups compar-
isons were performed by one-way of variance, and significant
intergroup's differences were assessed by Tukey-Kramer test. The
p values less than 0.05 were considered significant. 
Results
Plasma total IgE was statistically significant higher in
OVA sensitized rats as compared to VEH sensitized
control groups (437.6 ± 97.7 kU/l vs 159.2 ± 22.7 kU/l,
respectively; p<0.01). 
Development of asthma has been also confirmed by
histological examination. The analysis of microscopic
sections showed significant changes in number and
distribution of inflammatory cells in studied groups of
animals. In light microscopy based on general analysis
of lung section there were no significant differences in
number and localization of mast cells and migrated
cells in control groups (Fig. 1A (VEH/VEH), Fig. 1B
(VEH/OVA), and Fig. 1C (OVA/VEH)). In these ani-
mals single mast cells were localized mainly beside
blood vessels and in interalveolar septa and only single
neutrophils were observed. In lungs from asthmatic
animals (OVA/OVA) the number of mast cells
increased considerably and they had much more regu-
lar distribution (Fig. 2). The highest accumulation of
mast cells was present around bronchia, nearby blood
vessels, and in interalveolar septa. Mast cells in this
group were bigger in size and had much stronger
intensity of staining in comparison with control
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groups. The development of asthma caused also
marked mobilization of migrated cells, especially
eosinophils and neutrophils. Additionally in asthmatic
subjects epithelial lesion of bronchi and bronchioles
201Kynurenine in asthmatic rats
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(2): 201 (199-203) 
doi: 10.2478/v10042-008-0030-7
Fig.1 Lung of control animals (A.VEH/VEH, B.VEH/OVA, 
C. OVA/VEH), only single mast cells were visible. May-Grunwald
and Giemza stain (magnification ×200).
Fig. 2. Lung specimen of asthmatic animals, numerous mast cells
concentrated around bronchia, blood vessels, and interalveolar
septa. May-Grunwald and Giemza stain (magnification ×200).
Fig. 3. Fragment of a lung from control group (VEH/OVA). PAS
stain (magnification ×400).
Fig. 4. Fragment of a lung from rat with asthma (OVA/OVA),
numerous goblet cells in the epithelium of bronchus. PAS stain
(magnification ×400).
were observed. In certain cells changes in the shape
and epithelium shedding were present. The studied
animals had a different number of goblet cells. Only a
very few goblet cells were present in control groups
(Fig. 3). In contrast, in asthmatic subjects the increase
in airway epithelium goblet cells (Fig. 4) and also
edema of bronchial mucosa occurred. 
The concentration of KYN in the plasma was 1.7 ±
0.3 μM, 1.9 ± 0.4 μM, 1.6 ± 0.4 μM, and 1.7 ± 0.5 μM
for VEH/VEH, VEH/OVA, OVA/VEH, and
OVA/OVA, respectively. It remains also not statistical-
ly different between studied groups in the lungs (3.1 ±
0.6 nmol/g 2.7 ± 0.7 nmol/g, 2.9 ± 0.6 nmol/g, and 2.3
± 0.8 nmol/g for VEH/VEH, VEH/OVA, OVA/VEH,
and OVA/OVA, respectively) and in the liver (2.9 ± 0.3
nmol/g, 3.5 ± 0.7 nmol/g, 2.9 ± 0.4 nmol/g, and 3.0 ±
0.4 nmol/g for VEH/VEH, VEH/OVA, OVA/VEH, and
OVA/OVA, respectively).
Discussion
In the present study the experimental model asthma
has been induced by OVA-sensitization followed by
challenge with OVA. In OVA sensitized rats plasma
IgE has the highest values as compared to VEH sensi-
tized control groups. The increase in total IgE repre-
sents development of sensitization against ovalbumin.
Additionally, to further confirm the development of
experimental asthma, we perform histological exami-
nation. In light microscopy of the lung in asthmatic
animals (OVA/OVA), the number of eosinophils and
neutrophils increased considerably as compared to
control groups. In OVA/OVA group definitely also
much more mast cells were present. Mast cells were
localized around bronchia and nearby blood vessels.
They had a different activity which was observed as
different intensity of staining. Also epithelial lesion
and the increase in airway epithelium goblet cells and
edema of bronchial mucosa were present in asthmatic
subjects.
Rat, in comparison with other animals, e.g. mice,
demonstrates many features of airway allergy and
allergic asthma that are similar to human [6]. It is
known that rat develop both, immediate and late asth-
matic responses after allergen challenge or after non-
specific challenge [12]. In sensitized rat in response to
allergen challenge both, CD4+ and CD8+ cells are
activated and they express Th2 cytokines [13]. Never-
theless, rat is a weak bronchoconstrictor and more
agonist is necessary to produce the airways narrowing
similar to guinea pigs [14]. Therefore rat model of
asthma is focused mainly on inflammatory process,
which progresses during disease natural course. Thus,
rat model of asthma will contribute greatly to our
understanding the mechanisms of allergic inflamma-
tion underlining asthma. It should also improve trans-
lation of basic research on immune system regulation
into clinical practice.
There are two theories relating to the role of trypto-
phan metabolism in immune system regulation: the
depletion of tryptophan and the accumulation of tryp-
tophan metabolites [15]. Tryptophan depletion theory
is based on the finding that the breakdown of trypto-
phan dramatically reduced the supply of this most
energetically expensive amino acid to synthesize [7].
Kynurenine is the first product of tryptophan metabo-
lism that accumulates after kynurenine pathway acti-
vation. In the present study we measure the concentra-
tion of kynurenine in rats with experimental asthma.
We noticed that the concentration of kynurenine did
not differ between studied groups neither in plasma,
lungs nor in the liver. Kynurenine has been reported to
act as a potent apoptotic agent for activated T cells
resulting in decreased T-cell proliferation [9,16]. In
patients with bronchial asthma, there is only one avail-
able study showing that serum kynurenine was
increased [17]. Typically OVA sensitization and chal-
lenge leads to Th2 phenotype generation [13], and in
turn Th2 cytokines are released, mainly IL-4 and IL-
13. It is known that both of these cytokines suppress
indolamine 2,3 dioxygenase activity [18], which might
result in the decrease in kynurenine generation or at
least in the unchanged level in asthmatic subjects as
compared to control groups. It should also be pointed
out that in animal model of asthma together with
increasing allergen challenges after allergen sensitiza-
tion, the tolerance might develop [19]. Therefore the
lack of differences in kynurenine concentration
observed in the present study should be taken with
caution, and the precise mechanisms responsible for
the observed results need to be established. Also the
involvement of other kynurenine pathway metabolites
should be verified. 
In conclusion, the concentration of KYN remains
unchanged between asthmatic animals and control
groups. Further studies using rat model of asthma are
warranted to establish the role of the kynurenine path-
way regulation in asthma. 
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